Table 1 Clinical characteristics of patients with prolonged meropenem therapy (MT) > 4 weeks and controls (ICU-stay > 4 weeks and meropenem therapy ≤ 14 days)
Casesa | Controlsb | p | |
|---|---|---|---|
Number of patients | 36 | 108 | |
Duration of uninterrupted meropenem use, days, median (IQR) | 34 (31–39) | 9 (7–11) | <0.001 |
Age in years, median (IQR) | 63 (51–71) | 66 (56–73) | 0.26 |
Female sex, n (%) | 13 (36.1) | 36 (33.3) | 0.76 |
Days on ICU, median (IQR) | 66 (51.5–92.5) | 35 (31–45) | <0.001 |
Malignancy, n (% of all pts) | 17 (47.2) | 22 (20.4) | 0.002 |
SAPS score at admission, median (IQR) | 42 (35–48) | 39 (33–47) | 0.36 |
Medical patients, n (% of all pts) | 4 (11.1) | 45 (42.7) | 0.001 |
Neurological patients, n (% of all pts) | 6 (16.7) | 30 (26.9) | 0.22 |
Surgical patients, n (% of all pts) | 26 (72.2) | 34 (31.5) | <0.001 |
Number of operations, median (IQR)c | 14 (5–27) | 4 (3–7) | <0.001 |
Colonization/infection with carbapenem-susceptible, multidrug-resistant Enterobacteriaceae n (%) | 7 (19.4) | 7 (6.5) | 0.007 |
Type of infection, n (%) | |||
pneumonia | 4 (11.1) | 27 (25.0) | <0.001 |
peritonitis | 16 (44.4) | 5 (4.6) | |
mediastinitis | 6 (16.7) | 4 (3.7) | |
unclear focus | 10 (27.8) | 72 (66.7) | |
In-ICU-mortality, n (%) | 16 (44.4%) | 27 (25.0%) | 0.03 |